Due to the change in climate as well as other environmental factors, cancer is one of the causes of death for many individuals, one of them being in the lungs. These three clues that can be spotted in the hands may be clues to symptoms of lung cancer.
Express reports that around 47,000 people in the United Kingdom are diagnosed with lung cancer every year. One in 13 men and one in 15 women most likely suffer from the disease. While there are obvious symptoms such as coughing, blood in the phlegm, unusual weight loss, there are more subtle symptoms, and these can be found in the hands.
For starters, a person with lung cancer may see a change in their hands. Clubbing of the hands is a sign of possible lung cancer in a person. Specifically changes in the person’s nails and fingers and is also known as Hippocratic clubbing. It usually occurs in more than three people out of 10 who have non-small cell lung cancer and in only four people out of 100 with small-cell lung cancer.
Another sign of finger clubbing is the softening of the base of the nail, and the skin next to the nail bed becomes shiny. The second clue is the nails curving more than usual when looked at from the side. This particular sign is also referred to as Scarmouth’s sign.
The third clue in the hands is the ends of the fingers becoming larger in appearance. This is sometimes referred to as drumstick fingers.
People aged 40 and above are the ones mainly affected by lung cancer in the United Kingdom. More than four people out of 10 who suffer from lung cancer are aged 75 and above. The exception of which are smokers, who have a higher risk of suffering from this disease regardless of age, making up 72 percent of lung cancer cases. Non-smokers are also susceptible to lung cancer due to secondhand smoke, but not as much as smokers.
In case you or someone you know may have these symptoms, it is best to consult a doctor right away to get a proper diagnosis.


Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 



